Researchers at Kennedy Krieger Institute have made significant strides in improving the lives of patients with Tourette syndrome. Their recent publication highlights how behavioral therapies—an ...
In May 2024, Knight entered into an agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (now part of Collegium Pharmaceutical, Inc.; ...
Knight Therapeutics Inc. ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PMtm, an extended-release formulation of ...